Nasdaq Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share.
The Notification Letter does not impact the Company's listing on the Nasdaq Capital Market at this time. In accordance with Nasdaq Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until December 7, 2022, to regain compliance with Nasdaq Rule 5550(a)(2). To regain compliance, the Company's American Depositary Shares representing ordinary shares (“ADSs”) must have a closing bid price of at least US$1.00 per ADS for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by December 7, 2022, the Company may be eligible for additional time to regain compliance or may face delisting.
The Company's business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor the closing bid price of its ADSs and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Rules.
As previously reported, on April 22, 2022, the Company received a letter from Nasdaq notifying the Company that it was no longer in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq. In accordance with Nasdaq Rule 5810(c)(2)(A), within 45 calendar days of receiving this notice, the Company submitted a plan to regain compliance to Nasdaq. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the letter to evidence compliance.
Although Nasdaq notification letters described above have no immediate effect on the Company's listing on Nasdaq, and the Company is working on implementing plans to regain compliance with Nasdaq listing standards, there can be no assurance that the Company will be able to regain compliance with Nasdaq’s minimum stockholders’ equity requirement or minimum bid-price requirement for continued listing.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical company focused
Recent QNRX News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/10/2024 08:10:54 PM
- Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2024 08:00:53 PM
- Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 08:10:00 PM
- Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results • GlobeNewswire Inc. • 03/13/2024 08:05:00 PM
- Mixed Futures Amidst Quiet Economic Schedule; Oil Prices Climb • IH Market News • 03/13/2024 11:03:39 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/08/2024 09:06:10 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/08/2024 09:04:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:01:51 PM
- Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET • GlobeNewswire Inc. • 03/07/2024 09:05:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 03/06/2024 10:07:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:01:40 PM
- Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/04/2024 10:27:14 PM
- Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/27/2024 11:01:59 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/15/2024 05:15:38 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:11:42 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:50:20 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/13/2024 09:30:14 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/12/2024 10:12:12 PM
- Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product • GlobeNewswire Inc. • 02/08/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:05:22 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/18/2023 10:30:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 10:29:49 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM